Figure 6.

In vivo efficacy of a HER2 T-BsAb against intraperitoneal BER-luc xenografts. Mice were injected intraperitoneally with a DSRCT cell line stably transduced with luciferase (BER-luc). Tumor growth was monitored with an IVIS bioluminescent imager. Mice were treated intravenously with activated human T cells once weekly, intraperitoneally with T-BsAbs twice weekly, and subcutaneously with recombinant human IL-15/IL-15R-alpha once weekly. An untreated group (no treatment) and a group treated with an irrelevant BsAb (CD19xCD3), activated human T cells, and IL-15/IL-15R-alpha (CD19xCD3) were included as controls. (A) Plot of mean total flux (photons/second), indicating tumor size. (B) Plot of weight of mice in each group. (C) Plots of each treatment group showing individual mice. Error bars indicate standard error of the mean. (D) Mice were injected retro-orbitally with 50 μL D-luciferin (30 mg/mL) one minute before imaging, anesthetized with isoflurane, and situated in a supine position. A 10 second exposure was used for all images and other parameters are identical in all images to allow comparison across groups and timepoints. N = five mice per group. * = p < 0.05.